|By Business Wire||
|June 27, 2014 12:00 PM EDT||
Eckert & Ziegler Radiopharma GmbH has received a recommendation from the European Medicines Agency for approval of its pharmaceutical 68Ge/68Ga generators. This achievement marks the conclusion of a comprehensive decentralized evaluation procedure and the first time a gallium generator has been approved for the clinical development of highly specific diagnostic agents. Approval for sale in the respective countries is expected within the next one to two months.
Gallium generators provide an inexpensive alternative for radiolabeling diagnostic probes using positron emission tomography (PET), an imaging process that can be used to determine whether tissue is diseased. The process is mainly used in cancer treatment. Until now, fluorine-18 or carbon-11 PET radioisotopes have usually been used to radiolabel diagnostic probes; these radioisotopes are produced using cyclotrons that are capitally intensive, large-scale dedicated installations requiring millions in investment. In contrast, the gallium generator is approximately the size of a thermos and can be sourced for far less money, lowering costs and increasing flexibility at nuclear medicine clinics.
Once it has received approval, Eckert & Ziegler will also submit its documents to the U.S. Food and Drug Administration (FDA), establishing a Drug Master File with the agency. This will allow parties interested in developing new drugs to refer to the dossier and use the generator in clinical tests of medications and in other settings.
Dr. André Heß, Member of the Executive Board of Eckert & Ziegler AG and Head of the Radiopharma segment, says: “We are proud to have gotten the ball rolling on the world’s first approval of a pharmaceutical 68Ge/68Ga generator. We would also like to encourage academic research and development departments in the global pharmaceutical industry to introduce more substances that can be radiolabeled with Ga-68 into clinical development. ‘Theranostic’ approaches that combine diagnosis using Ga-68 PET with treatment using Yttrium-90, coupled using the same carrier molecule, are also very promising.”
Eckert & Ziegler operates a network of cyclotrons in central and eastern Europe and manufactures pharmaceutical Yttrium-90 (EU-approved product: Yttriga). The company has developed a customized technology platform for the local production of radiopharmaceuticals (designed especially for Ga-68 and Y-90-based pharmaceuticals) that allows clinical users to perform all processes, from synthesis and quality control to patient dose preparation.
Eckert & Ziegler (ISIN DE0005659700), with approximately 700 employees, is one the world’s largest providers of isotope technology for radiation therapy and nuclear medicine.
DevOps at Cloud Expo, taking place Nov 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with 19th Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is no time to wait for long dev...
Aug. 25, 2016 02:30 AM EDT Reads: 2,117
Aug. 25, 2016 02:15 AM EDT Reads: 397
Aug. 25, 2016 02:00 AM EDT Reads: 1,887
Aug. 25, 2016 02:00 AM EDT Reads: 1,762
Aug. 25, 2016 01:15 AM EDT Reads: 1,594
Aug. 25, 2016 01:00 AM EDT Reads: 1,952
Aug. 25, 2016 12:45 AM EDT Reads: 1,899
Aug. 25, 2016 12:30 AM EDT Reads: 2,055
Aug. 25, 2016 12:00 AM EDT Reads: 2,962
Aug. 24, 2016 10:30 PM EDT Reads: 1,446
Aug. 24, 2016 10:30 PM EDT Reads: 2,010
Aug. 24, 2016 09:15 PM EDT Reads: 1,664
Aug. 24, 2016 04:45 PM EDT Reads: 1,303
Aug. 24, 2016 04:15 PM EDT Reads: 356
Aug. 24, 2016 04:15 PM EDT Reads: 484